SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-075598
Filing Date
2019-12-23
Accepted
2019-12-23 16:19:02
Documents
10
Period of Report
2019-12-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm1926567-5_8k.htm 8-K 17686
2 EXHIBIT 5.1 tm1926567d5_ex5-1.htm EX-5.1 27658
3 EXHIBIT 5.2 tm1926567d5_ex5-2.htm EX-5.2 15441
4 GRAPHIC tm1926567d5_ex5-1img001.jpg GRAPHIC 2509
5 GRAPHIC tm1926567d5_ex5-1img002.jpg GRAPHIC 6372
6 GRAPHIC tm1926567d5_ex5-1img003.jpg GRAPHIC 2169
7 GRAPHIC tm1926567d5_ex5-2img001.jpg GRAPHIC 1958
8 GRAPHIC tm1926567d5_ex5-2img002.jpg GRAPHIC 7591
9 GRAPHIC tm1926567d5_ex5-2img003.jpg GRAPHIC 1958
10 GRAPHIC tm1926567d5_ex5-2img004.jpg GRAPHIC 1958
  Complete submission text file 0001104659-19-075598.txt   96912
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 191306294
SIC: 2834 Pharmaceutical Preparations